Combining Navelbine and Medroxyprogesterone Acetate for Breast Cancer Treatment
Author Information
Author(s): K Sugiyama, M Shimizu, T Akiyama, H Ishida, M Okabe, T Tamaoki, S Akinaga
Primary Institution: Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo
Hypothesis
Does the combination of Navelbine and Medroxyprogesterone Acetate enhance the treatment efficacy against human breast carcinoma MCF-7 cells?
Conclusion
The combination of Navelbine and Medroxyprogesterone Acetate shows a synergistic effect in inhibiting the growth of breast cancer cells.
Supporting Evidence
- The combination of Navelbine and Medroxyprogesterone Acetate was shown to be synergistic in inhibiting MCF-7 cell growth.
- Navelbine induced G1-phase accumulation and increased expression of the CDK inhibitor p21WAF1/cIPl.
- MPA reduced cyclin D1 protein expression, contributing to G1-phase accumulation.
- The combined treatment was effective in other breast cancer cell lines as well.
Takeaway
Using two medicines together can work better than using them alone to fight breast cancer cells.
Methodology
The study used isobologram and median-effect plot analyses to assess the combined effects of Navelbine and Medroxyprogesterone Acetate on MCF-7 cells in vitro.
Limitations
The study was conducted in vitro, and results may not directly translate to clinical outcomes in patients.
Want to read the original?
Access the complete publication on the publisher's website